Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: Role of lamivudine prophylaxis

被引：31

作者：

Coiffier, Bertrand ^{[1
]}

机构：

[1] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France

来源：

CANCER INVESTIGATION | 2006年 / 24卷 / 05期

关键词：

D O I：

10.1080/07357900600815232

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatitis B virus (HBV) reactivation is a frequent complication in inactive HBV carriers at time of chemotherapy or following this chemotherapy. This complication appeared during or after chemotherapy and was not increased by the use of rituximab alone or combined with chemotherapy. This is a severe complication most frequently seen in lymphoma patients. Lamivudine have efficacy to treat the patients once the clinical disease is present. However, lamivudine prophylaxis beginning before chemotherapy and until at least 6 months after the end of chemotherapy is recommended for all HBV carriers. Hepatitis C virus is usually not associated with reactivation and prophylaxis should not be used.

引用

页码：548 / 552

页数：5

共 87 条

[1]

Ahmed A, 1999, AM J GASTROENTEROL, V94, P249, DOI 10.1111/j.1572-0241.1999.00808.x

[2] Prevention of hepatitis B flare-up during chemotherapy using lamivudine:: case report and review of the literature [J].